Book an Appointment

Positive Results for Phase 3 Trial of Oral Immunotherapy for Patients with Peanut Allergy

Positive Results for Phase 3 Trial of Oral Immunotherapy for Patients with Peanut Allergy
Positive Results for Phase 3 Trial of Oral Immunotherapy for Patients with Peanut Allergy

Therapeutics

Aimmune Therapeutics is a biopharmaceutical company that is investigating oral immunotherapy as a treatment for food allergy. Currently there is no F.D.A approved treatment for food allergy. Options
for patient with food allergy include food avoidance and carrying an epinephrine auto-injector in case of accidental ingestion.Aimmune presented its most recent research findings of their Phase 3 trial at the 2018 AAAAI/WAO Joint Congress conference in Orlando, Florida. Notably, in the 554 patient study, 67.2% of the patients aged 4-17 who received the experimental treatment tolerated at least 600 mg dose of peanut protein in a food challenge compared to 4% of patients who received the placebo.Currently in the US, the drug is in the FDA Breakthrough Drug Designation and is in the process of being fast-tracked for possible approval. For more information, please click here

Make sure to follow and like us on social media including facebook, twitter and instagram to get the latest breaking news in allergy and immunology.